Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc. is a market leader in long-acting injectable medications for opioid use disorder (OUD). The company focuses on providing evidence-based drug therapies for OUD and aims to improve understanding of OUD as a chronic, relapsing, but treatable brain disease. For over 25 years, Indivior has innovated in addiction medicine, creating distinct therapeutic solutions that support patient recovery, increase access to care, and provide value for patients, healthcare systems, and stockholders. Indivior is headquartered in Richmond, Virginia, U.S. Indivior's product portfolio is primarily available in the U.S., with additional products in Canada, Australia, France, and Germany. Its core approved treatments for OUD include SUBLOCADE (buprenorphine extended-release monthly injection) and SUBOXONE Film (buprenorphine and naloxone sublingual film). Product availability, including dosage, strength, and indication, varies across these countries. The U.S. is Indivior's core geographic market, based on where sales originate, and accounted for 85% of net revenues for the year ended December 31, 2025, 85% for 2024, and 83% for 2023. In the U.S., the company sells only SUBLOCADE and SUBOXONE Film. Indivior's business was initially a division of Reckitt Benckiser Group PLC. Indivior PLC was incorporated on September 26, 2014, to acquire this specialty pharmaceutical business unit, becoming a standalone business effective December 23, 2014. On December 11, 2025, stockholders approved a plan to change the company's domicile to the U.S.